References

1. Forti, G.; Krausz, C. Clinical review 100: Evaluation and treatment of the infertile couple. J. Clin. Endocrinol. Metab. 1998, 83, 4177–4188.
2. Lotti, F.; Maggi, M. Sexual dysfunction and male infertility. Nat. Rev. Urol. 2018, 15, 287–307.
3. Tournaye, H.; Krausz, C.; Oates, R.D. Novel concepts in the aetiology of male reproductive impairment. Lancet Diabetes Endocrinol. 2017, 5, 544–553.
4. Krausz, C.; Cioppi, F.; Riera-Escamilla, A. Testing for genetic contributions to infertility: Potential clinical impact. Expert Rev. Mol. Diagn. 2018, 18, 331–346.
5. Krausz, C.; Riera-Escamilla, A. Genetics of male infertility. Nat. Rev. Urol. 2018, 15, 369–384.
6. Krausz, C.; Hoefsloot, L.; Simoni, M.; Tüttelmann, F.; European Academy of Andrology. European Molecular Genetics Quality Network EAA/EMQN best practice guidelines for molecular diagnosis of Y-chromosomal microdeletions: State-of-the-art 2013. Andrology 2014, 2, 5–19.
7. Cangiano, B.; Swee, D.S.; Quinton, R.; Bonomi, M. Genetics of congenital hypogonadotropic hypogonadism: Peculiarities and phenotype of an oligogenic disease. Hum. Genet. 2021, 140, 77–111.
8. Butz, H.; Nyírő, G.; Kurucz, P.A.; Likó, I.; Patócs, A. Molecular genetic diagnostics of hypogonadotropic hypogonadism: From panel design towards result interpretation in clinical practice. Hum. Genet. 2021, 140, 113–134.
9. Oud, M.S.; Volozonoka, L.; Smits, R.M.; Vissers, L.E.L.M.; Ramos, L.; Veltman, J.A. A systematic review and standardized clinical validity assessment of male infertility genes. Hum. Reprod. 2019, 34, 932–941.
10. Krausz, C.; Riera-Escamilla, A.; Moreno-Mendoza, D.; Holleman, K.; Cioppi, F.; Algaba, F.; Pybus, M.; Friedrich, C.; Wyrwoll, M.J.; Casamonti, E.; et al. Genetic dissection of spermatogenic arrest through exome analysis: Clinical implications for the management of azoospermic men. Genet. Med. 2020, 22, 1956–1966.
11. Kasak, L.; Laan, M. Monogenic causes of non-obstructive azoospermia: Challenges, established knowledge, limitations and perspectives. Hum. Genet. 2021, 140, 135–154.
12. Klinefelter, H.F.; Reifenstein, E.C.; Albright, F. Syndrome characterized by gynecomastia, aspermatogenesis without A-Leydigism, and increased excretion of follicle-stimulating hormone1. J. Clin. Endocrinol. Metab. 1942, 2, 615–627.
13. Zitzmann, M.; Aksglaede, L.; Corona, G.; Isidori, A.M.; Juul, A.; T’Sjoen, G.; Kliesch, S.; D’Hauwers, K.; Toppari, J.; Słowikowska-Hilczer, J.; et al. European academy of andrology guidelines on Klinefelter Syndrome: Endorsing Organization: European Society of Endocrinology. Andrology 2021, 9, 145–167.
14. Vloeberghs, V.; Verheyen, G.; Santos-Ribeiro, S.; Staessen, C.; Verpoest, W.; Gies, I.; Tournaye, H. Is genetic fatherhood within reach for all azoospermic Klinefelter men? PLoS ONE 2018, 13.
15. Abramsky, L.; Chapple, J. 47,XXY (Klinefelter Syndrome) and 47,XYY: Estimated rates of and indication for postnatal diagnosis with implications for prenatal counselling. Prenat. Diagn. 1997, 17, 363–368.
16. Bojesen, A.; Juul, S.; Gravholt, C.H. Prenatal and postnatal prevalence of Klinefelter syndrome: A national registry study. J. Clin. Endocrinol. Metab. 2003, 88, 622–626.
17. Bojesen, A.; Gravholt, C.H. Klinefelter syndrome in clinical practice. Nat. Clin. Pract. Urol. 2007, 4, 192–204.
18. Gravholt, C.H.; Chang, S.; Wallentin, M.; Fedder, J.; Moore, P.; Skakkebæk, A. Klinefelter syndrome: Integrating genetics, neuropsychology, and endocrinology. Endocr. Rev. 2018, 39, 389–423.
19. Ottesen, A.M.; Aksglaede, L.; Garn, I.; Tartaglia, N.; Tassone, F.; Gravholt, C.H.; Bojesen, A.; Sørensen, K.; Jørgensen, N.; De Meyts, E.R.; et al. Increased number of sex chromosomes affects height in a nonlinear fashion: A study of 305 patients with sex chromosome aneuploidy. Am. J. Med. Genet. Part A 2010, 152, 1206–1212.
20. Zitzmann, M.; Depenbusch, M.; Jörg Gromoll, A.; Nieschlag, E. X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in klinefelter patients. J. Clin. Endocrinol. Metab. 2004, 89, 6208–6217.
21. Bojesen, A.; Hertz, J.M.; Gravholt, C.H. Genotype and phenotype in Klinefelter syndrome-impact of androgen receptor polymorphism and skewed X inactivation. Int. J. Androl. 2011, 34.
22. Chang, S.; Skakkebæk, A.; Trolle, C.; Bojesen, A.; Hertz, J.M.; Cohen, A.; Hougaard, D.M.; Wallentin, M.; Pedersen, A.D.; Østergaard, J.R.; et al. Anthropometry in klinefelter syndrome-multifactorial influences due to CAG length, testosterone treatment and possibly intrauterine hypogonadism. J. Clin. Endocrinol. Metab. 2015, 100, E508–E517.
23. Belling, K.; Russo, F.; Jensen, A.B.; Dalgaard, M.D.; Westergaard, D.; De Meyts, E.R.; Skakkebaek, N.E.; Juul, A.; Brunak, S. Klinefelter syndrome comorbidities linked to increased X chromosome gene dosage and altered protein interactome activity. Hum. Mol. Genet. 2017, 26, 1219–1229.
24. Sharma, A.; Jamil, M.A.; Nuesgen, N.; Schreiner, F.; Priebe, L.; Hoffmann, P.; Herns, S.; Nöthen, M.M.; Fröhlich, H.; Oldenburg, J.; et al. DNA methylation signature in peripheral blood reveals distinct characteristics of human X chromosome numerical aberrations. Clin. Epigenetics 2015, 7, 1–15.
25. Viana, J.; Pidsley, R.; Troakes, C.; Spiers, H.; Wong, C.C.Y.; Al-Sarraj, S.; Craig, I.; Schalkwyk, L.; Mill, J. Epigenomic and transcriptomic signatures of a Klinefelter syndrome (47,XXY) karyotype in the brain. Epigenetics 2014, 9, 587–599.
26. Stochholm, K.; Juul, S.; Gravholt, C.H. Poor socio-economic status in 47,XXX-An unexpected effect of an extra X chromosome. Eur. J. Med. Genet. 2013, 56, 286–291.
27. Davis, S.M.; Rogol, A.D.; Ross, J.L. Testis Development and fertility potential in boys with Klinefelter syndrome. Endocrinol. Metab. Clin. N. Am. 2015, 44, 843–865.
28. Levron, J.; Aviram-Goldring, A.; Madgar, I.; Raviv, G.; Barkai, G.; Dor, J. Sperm chromosome analysis and outcome of IVF in patients with non-mosaic Klinefelter’s syndrome. Fertil. Steril. 2000, 74, 925–929.
29. Sciurano, R.B.; Luna Hisano, C.V.; Rahn, M.I.; Brugo Olmedo, S.; Rey Valzacchi, G.; Coco, R.; Solari, A.J. Focal spermatogenesis originates in euploid germ cells in classical Klinefelter patients. Hum. Reprod. 2009, 24, 2353–2360.
30. Corona, G.; Pizzocaro, A.; Lanfranco, F.; Garolla, A.; Pelliccione, F.; Vignozzi, L.; Ferlin, A.; Foresta, C.; Jannini, E.A.; Maggi, M.; et al. Sperm recovery and ICSI outcomes in Klinefelter syndrome: A systematic review and meta-analysis. Hum. Reprod. Update 2017, 23, 1–11.
31. Rohayem, J.; Fricke, R.; Czeloth, K.; Mallidis, C.; Wistuba, J.; Krallmann, C.; Zitzmann, M.; Kliesch, S. Age and markers of Leydig cell function, but not of Sertoli cell function predict the success of sperm retrieval in adolescents and adults with Klinefelter’s syndrome. Andrology 2015, 3, 868–875.
32. Gies, I.; Tournaye, H.; De Schepper, J. Attitudes of parents of Klinefelter boys and pediatricians towards neonatal screening and fertility preservation techniques in Klinefelter syndrome. Eur. J. Pediatr. 2016, 175, 399–404.
33. Greco, E.; Scarselli, F.; Minasi, M.G.; Casciani, V.; Zavaglia, D.; Dente, D.; Tesarik, J.; Franco, G. Birth of 16 healthy children after ICSI in cases of nonmosaic Klinefelter syndrome. Hum. Reprod. 2013, 28, 1155–1160.
34. Fullerton, G.; Hamilton, M.; Maheshwari, A. Should non-mosaic Klinefelter syndrome men be labelled as infertile in 2009? Hum. Reprod. 2010, 25, 588–597.
35. Denschlag, D.; Tempfer, C.; Kunze, M.; Wolff, G.; Keck, C. Assisted reproductive techniques in patients with Klinefelter syndrome: A critical review. Fertil. Steril. 2004, 82, 775–779.
36. Maiburg, M.; Repping, S.; Giltay, J. The genetic origin of Klinefelter syndrome and its effect on spermatogenesis. Fertil. Steril. 2012, 98, 253–260.
37. De la Chapelle, A.; Hortling, H.; Niemi, M.; Wennström, J. XX Sex Chromosomes in a Human Male. Acta Med. Scand. 1964, 175, 25–38.
38. Vorona, E.; Zitzmann, M.; Gromoll, J.; Schüring, A.N.; Nieschlag, E. Clinical, endocrinological, and epigenetic features of the 46,XX male syndrome, compared with 47,XXY Klinefelter patients. J. Clin. Endocrinol. Metab. 2007, 92, 3458–3465.
39. Kousta, E.; Papathanasiou, A.; Skordis, N. Sex determination and disorders of sex development according to the revised nomenclature and classification in 46,XX individuals. Hormones 2010, 9, 218–231.
40. McElreavey, K.; Vilain, E.; Abbas, N.; Herskowitz, I.; Fellous, M. A regulatory cascade hypothesis for mammalian sex determination: SRY represses a negative regulator of male development. Proc. Natl. Acad. Sci. USA 1993, 90, 3368–3372.
41. Sutton, E.; Hughes, J.; White, S.; Sekido, R.; Tan, J.; Arboleda, V.; Rogers, N.; Knower, K.; Rowley, L.; Eyre, H.; et al. Identification of SOX3 as an XX male sex reversal gene in mice and humans. J. Clin. Investig. 2011, 121, 328–341.
42. Chiang, H.-S.; Wu, Y.-N.; Wu, C.-C.; Hwang, J.-L. Cytogenic and molecular analyses of 46,XX male syndrome with clinical comparison to other groups with testicular azoospermia of genetic origin. J. Formos. Med. Assoc. 2013, 112, 72–78.
43. Baxter, R.M.; Vilain, E. Translational genetics for diagnosis of human disorders of sex development. Annu. Rev. Genomics Hum. Genet. 2013, 14, 371–392.
44. Skaletsky, H.; Kuroda-Kawaguchi, T.; Minx, P.J.; Cordum, H.S.; Hillier, L.; Brown, L.G.; Repping, S.; Pyntikova, T.; Ali, J.; Bieri, T.; et al. The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. Nature 2003, 423, 825–837.
45. Navarro-Costa, P. Sex, rebellion and decadence: The scandalous evolutionary history of the human Y chromosome. Biochim. Biophys. Acta Mol. Basis Dis. 2012, 1822, 1851–1863.
46. Tiepolo, L.; Zuffardi, O. Localization of factors controlling spermatogenesis in the nonfluorescent portion of the human Y chromosome long arm. Hum. Genet. 1976, 34, 119–124.
47. Vogt, P.H.; Edelmann, A.; Kirsch, S.; Henegariu, O.; Hirschmann, P.; Kiesewetter, F.; Köhn, F.M.; Schill, W.B.; Farah, S.; Ramos, C.; et al. Human Y chromosome azoospermia factors (AZF) mapped to different subregions in Yq11. Hum. Mol. Genet. 1996, 5, 933–943.
48. Turner, J.M.A.; Mahadevaiah, S.K.; Fernandez-Capetillo, O.; Nussenzweig, A.; Xu, X.; Deng, C.X.; Burgoyne, P.S. Silencing of unsynapsed meiotic chromosomes in the mouse. Nat. Genet. 2005, 37, 41–47.
49. Krausz, C.; Casamonti, E. Spermatogenic failure and the Y chromosome. Hum. Genet. 2017, 136, 637–655.
50. Lo Giacco, D.; Chianese, C.; Sánchez-Curbelo, J.; Bassas, L.; Ruiz, P.; Rajmil, O.; Sarquella, J.; Vives, A.; Ruiz-Castañé, E.; Oliva, R.; et al. Clinical relevance of Y-linked CNV screening in male infertility: New insights based on the 8-year experience of a diagnostic genetic laboratory. Eur. J. Hum. Genet. 2014, 22, 754–761.
51. Ginalski, K.; Rychlewski, L.; Baker, D.; Grishin, N.V. Protein structure prediction for the male-specific region of the human Y chromosome. Proc. Natl. Acad. Sci. USA 2004, 101, 2305–2310.
52. Tyler-Smith, C.; Krausz, C. The will-o’-the-wisp of genetics—Hunting for the azoospermia factor gene. N. Engl. J. Med. 2009, 360, 925–927.
53. Mohr, S.; Stryker, J.M.; Lambowitz, A.M. A DEAD-Box protein functions as an ATP-dependent RNA chaperone in group I intron splicing. Cell 2002, 109, 769–779.
54. Wu, Q.; Chen, G.W.; Yan, T.F.; Wang, H.; Liu, Y.L.; Li, Z.; Duan, S.W.; Sun, F.; Feng, Y.; Shi, H.J. Prevalent false positives of azoospermia factor a (AZFa) microdeletions caused by single-nucleotide polymorphism rs72609647 in the sY84 screening of male infertility. Asian J. Androl. 2011, 13, 877–880.
55. Stouffs, K.; Vloeberghs, V.; Gheldof, A.; Tournaye, H.; Seneca, S. Are AZFb deletions always incompatible with sperm production? Andrology 2017, 5, 691–694.
56. Flannigan, R.; Schlegel, P.N. Genetic diagnostics of male infertility in clinical practice. Best Pract. Res. Clin. Obstet. Gynaecol. 2017, 44, 26–37.
57. Jaruzelska, J.; Korcz, A.; Wojda, A.; Jedrzejczak, P.; Bierla, J.; Surmacz, T.; Pawelczyk, L.; Page, D.C.; Kotecki, M. Mosaicism for 45,X cell line may accentuate the severity of spermatogenic defects in men with AZFc deletion. J. Med. Genet. 2001, 38, 798–802.
58. Siffroi, J.P.; Le Bourhis, C.; Krausz, C.; Barbaux, S.; Quintana-Murci, L.; Kanafani, S.; Rouba, H.; Bujan, L.; Bourrouillou, G.; Seifer, I.; et al. Sex chromosome mosaicism in males carrying Y chromosome long arm deletions. Hum. Reprod. 2000, 15, 2559–2562.
59. Patsalis, P.C.; Skordis, N.; Sismani, C.; Kousoulidou, L.; Koumbaris, G.; Eftychi, C.; Stavrides, G.; Ioulianos, A.; Kitsiou-Tzeli, S.; Galla-Voumvouraki, A.; et al. Identification of high frequency of Y chromosome deletions in patients with sex chromosome mosaicism and correlation with the clinical phenotype and Y-chromosome instability. Am. J. Med. Genet. 2005, 135, 145–149.
60. Krausz, C.; Degl’Innocenti, S. Y chromosome and male infertility: Update, 2006. Front. Biosci. 2006, 11, 3049–3061.
61. Le Bourhis, C.; Siffroi, J.P.; McElreavey, K.; Dadoune, J.P. Y chromosome microdeletions and germinal mosaicism in infertile males. Mol. Hum. Reprod. 2000, 6, 688–693.
62. Young, J.; Xu, C.; Papadakis, G.E.; Acierno, J.S.; Maione, L.; Hietamäki, J.; Raivio, T.; Pitteloud, N. Clinical management of congenital hypogonadotropic hypogonadism. Endocr. Rev. 2019, 40, 669–710.
63. Boehm, U.; Bouloux, P.-M.; Dattani, M.T.; de Roux, N.; Dodé, C.; Dunkel, L.; Dwyer, A.A.; Giacobini, P.; Hardelin, J.-P.; Juul, A.; et al. European Consensus Statement on congenital hypogonadotropic hypogonadism—Pathogenesis, diagnosis and treatment. Nat. Rev. Endocrinol. 2015, 11, 547–564.
64. Dwyer, A.A.; Raivio, T.; Pitteloud, N. Reversible hypogonadotropic hypogonadism. Eur. J. Endocrinol. 2016, 174, R267–R274.
65. Bieth, E.; Hamdi, S.M.; Mieusset, R. Genetics of the congenital absence of the vas deferens. Hum. Genet. 2021, 140, 59–76.
66. Oates, R.D.; Amos, J.A. The genetic basis of congenital bilateral absence of the vas deferens and cystic fibrosis. J. Androl. 1994, 15, 1–8.
67. Bergougnoux, A.; Délétang, K.; Pommier, A.; Varilh, J.; Houriez, F.; Altieri, J.P.; Koenig, M.; Férec, C.; Claustres, M.; Lalau, G.; et al. Functional characterization and phenotypic spectrum of three recurrent disease-causing deep intronic variants of the CFTR gene. J. Cyst. Fibros. 2019, 18, 468–475.
68. Feng, J.; Wu, X.; Zhang, Y.; Yang, X.; Ma, G.; Chen, S.; Luo, S.; Zhang, Y. A novel mutation (−195C>A) in the promoter region of CFTR gene is associated with Chinese Congenital Bilateral Absence of Vas Deferens (CBAVD). Gene 2019, 719.
69. De Souza, D.A.S.; Faucz, F.R.; Pereira-Ferrari, L.; Sotomaior, V.S.; Raskin, S. Congenital bilateral absence of the vas deferens as an atypical form of cystic fibrosis: Reproductive implications and genetic counseling. Andrology 2018, 6, 127–135.
70. Deignan, J.L.; Astbury, C.; Cutting, G.R.; del Gaudio, D.; Gregg, A.R.; Grody, W.W.; Monaghan, K.G.; Richards, S. CFTR variant testing: A technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 2020, 22, 1288–1295.
71. Obermann, H.; Samalecos, A.; Osterhoff, C.; Schröder, B.; Heller, R.; Kirchhoff, C. HE6, a two-subunit heptahelical receptor associated with apical membranes of efferent and epididymal duct epithelia. Mol. Reprod. Dev. 2003, 64, 13–26.
72. Patat, O.; Pagin, A.; Siegfried, A.; Mitchell, V.; Chassaing, N.; Faguer, S.; Monteil, L.; Gaston, V.; Bujan, L.; Courtade-Saïdi, M.; et al. Truncating mutations in the adhesion g protein-coupled receptor G2 Gene ADGRG2 cause an X-linked congenital bilateral absence of vas deferens. Am. J. Hum. Genet. 2016, 99, 437–442.
73. Davies, B.; Baumann, C.; Kirchhoff, C.; Ivell, R.; Nubbemeyer, R.; Habenicht, U.-F.; Theuring, F.; Gottwald, U. targeted deletion of the epididymal receptor HE6 results in fluid dysregulation and male infertility. Mol. Cell. Biol. 2004, 24, 8642–8648.
74. Yang, B.; Wang, J.; Zhang, W.; Pan, H.; Li, T.; Liu, B.; Li, H.; Wang, B. Pathogenic role of ADGRG2 in CBAVD patients replicated in Chinese population. Andrology 2017, 5, 954–957.
75. Khan, M.J.; Pollock, N.; Jiang, H.; Castro, C.; Nazli, R.; Ahmed, J.; Basit, S.; Rajkovic, A.; Yatsenko, A.N. X-linked ADGRG2 mutation and obstructive azoospermia in a large Pakistani family. Sci. Rep. 2018, 8, 1–7.
76. Yuan, P.; Liang, Z.K.; Liang, H.; Zheng, L.Y.; Li, D.; Li, J.; Zhang, J.; Tian, J.; Lai, L.H.; Zhang, K.; et al. Expanding the phenotypic and genetic spectrum of Chinese patients with congenital absence of vas deferens bearing CFTR and ADGRG2 alleles. Andrology 2019, 7, 329–340.
77. Pagin, A.; Bergougnoux, A.; Girodon, E.; Reboul, M.P.; Willoquaux, C.; Kesteloot, M.; Raynal, C.; Bienvenu, T.; Humbert, M.; Lalau, G.; et al. Novel ADGRG2 truncating variants in patients with X-linked congenital absence of vas deferens. Andrology 2020, 8, 618–624.
78. Wu, Y.-N.; Lin, Y.-H.; Chiang, H.-S. SLC9A3 is a novel pathogenic gene in Taiwanese males with congenital bilateral absence of the vas deferens. Eur. Urol. Suppl. 2018, 17, e1092.
79. Wu, Y.N.; Chen, K.C.; Wu, C.C.; Lin, Y.H.; Chiang, H.S. SLC9A3 affects vas deferens development and associates with taiwanese congenital bilateral absence of the vas deferens. Biomed. Res. Int. 2019, 2019.
80. Chalmel, F.; Lardenois, A.; Evrard, B.; Mathieu, R.; Feig, C.; Demougin, P.; Gattiker, A.; Schulze, W.; Jégou, B.; Kirchhoff, C.; et al. Global human tissue profiling and protein network analysis reveals distinct levels of transcriptional germline-specificity and identifies target genes for male infertility. Hum. Reprod. 2012, 27, 3233–3248.
81. Soraggi, S.; Riera, M.; Rajpert-De Meyts, E.; Schierup, M.H.; Almstrup, K. Evaluating genetic causes of azoospermia: What can we learn from a complex cellular structure and single-cell transcriptomics of the human testis? Hum. Genet. 2021, 140, 183–201.
82. Krausz, C.; Riera-Escamilla, A.; Chianese, C.; Moreno-Mendoza, D.; Ars, E.; Rajmil, O.; Pujol, R.; Bogliolo, M.; Blanco, I.; Rodríguez, I.; et al. From exome analysis in idiopathic azoospermia to the identification of a high-risk subgroup for occult Fanconi anemia. Genet. Med. 2019, 21, 189–194.
83. Miyamoto, T.; Bando, Y.; Koh, E.; Tsujimura, A.; Miyagawa, Y.; Iijima, M.; Namiki, M.; Shiina, M.; Ogata, K.; Matsumoto, N.; et al. A PLK4 mutation causing azoospermia in a man with Sertoli cell-only syndrome. Andrology 2016, 4, 75–81.
84. Fakhro, K.A.; Elbardisi, H.; Arafa, M.; Robay, A.; Rodriguez-Flores, J.L.; Al-Shakaki, A.; Syed, N.; Mezey, J.G.; Abi Khalil, C.; Malek, J.A.; et al. Point-of-care whole-exome sequencing of idiopathic male infertility. Genet. Med. 2018, 20, 1365–1373.
85. Fan, S.; Jiao, Y.; Khan, R.; Jiang, X.; Javed, A.R.; Ali, A.; Zhang, H.; Zhou, J.; Naeem, M.; Murtaza, G.; et al. Homozygous mutations in C14orf39/SIX6OS1 cause non-obstructive azoospermia and premature ovarian insufficiency in humans. Am. J. Hum. Genet. 2021, 108.
86. He, W.B.; Tu, C.F.; Liu, Q.; Meng, L.L.; Yuan, S.M.; Luo, A.X.; He, F.S.; Shen, J.; Li, W.; Du, J.; et al. DMC1 mutation that causes human non-obstructive azoospermia and premature ovarian insufficiency identified by whole-exome sequencing. J. Med. Genet. 2018, 55, 198–204.
87. Salas-Huetos, A.; Tüttelmann, F.; Wyrwoll, M.J.; Kliesch, S.; Lopes, A.M.; Conçalves, J.; Boyden, S.E.; Wöste, M.; Hotaling, J.M.; Aston, K.I.; et al. Disruption of human meiotic telomere complex genes TERB1, TERB2 and MAJIN in men with non-obstructive azoospermia. Hum. Genet. 2020, 140, 217–227.
88. Ben Khelifa, M.; Ghieh, F.; Boudjenah, R.; Hue, C.; Fauvert, D.; Dard, R.; Garchon, H.J.; Vialard, F. A MEI1 homozygous missense mutation associated with meiotic arrest in a consanguineous family. Hum. Reprod. 2018, 33, 1034–1037.
89. Nguyen, N.M.P.; Ge, Z.J.; Reddy, R.; Fahiminiya, S.; Sauthier, P.; Bagga, R.; Sahin, F.I.; Mahadevan, S.; Osmond, M.; Breguet, M.; et al. Causative mutations and mechanism of androgenetic hydatidiform moles. Am. J. Hum. Genet. 2018, 103, 740–751.
90. Gershoni, M.; Hauser, R.; Yogev, L.; Lehavi, O.; Azem, F.; Yavetz, H.; Pietrokovski, S.; Kleiman, S.E. A familial study of azoospermic men identifies three novel causative mutations in three new human azoospermia genes. Genet. Med. 2017, 19, 998–1006.
91. Gershoni, M.; Hauser, R.; Barda, S.; Lehavi, O.; Arama, E.; Pietrokovski, S.; Kleiman, S.E. A new MEIOB mutation is a recurrent cause for azoospermia and testicular meiotic arrest. Hum. Reprod. 2019, 34, 666–671.
92. Riera-Escamilla, A.; Enguita-Marruedo, A.; Moreno-Mendoza, D.; Chianese, C.; Sleddens-Linkels, E.; Contini, E.; Benelli, M.; Natali, A.; Colpi, G.M.; Ruiz-Castañé, E.; et al. Sequencing of a “mouse azoospermia” gene panel in azoospermic men: Identification of RNF212 and STAG3 mutations as novel genetic causes of meiotic arrest. Hum. Reprod. 2019, 34, 978–988.
93. Becherel, O.J.; Fogel, B.L.; Zeitlin, S.I.; Samaratunga, H.; Greaney, J.; Homer, H.; Lavin, M.F. Disruption of spermatogenesis and infertility in ataxia with oculomotor apraxia type 2 (AOA2). Cerebellum 2019, 18, 448–456.
94. Catford, S.R.; O’Bryan, M.K.; McLachlan, R.I.; Delatycki, M.B.; Rombauts, L. Germ cell arrest associated with aSETX mutation in ataxia oculomotor apraxia type 2. Reprod. Biomed. Online 2019, 38, 961–965.
95. Yao, C.; Yang, C.; Zhao, L.; Li, P.; Tian, R.; Chen, H.; Guo, Y.; Huang, Y.; Zhi, E.; Zhai, J.; et al. Bi-allelic SHOC1 loss-of-function mutations cause meiotic arrest and non-obstructive azoospermia. J. Med. Genet. 2020.
96. Kherraf, Z.-E.; Christou-Kent, M.; Karaouzene, T.; Amiri-Yekta, A.; Martinez, G.; Vargas, A.S.; Lambert, E.; Borel, C.; Dorphin, B.; Aknin-Seifer, I.; et al. SPINK2 deficiency causes infertility by inducing sperm defects in heterozygotes and azoospermia in homozygotes. EMBO Mol. Med. 2017, 9, 1132–1149.
97. Jaillard, S.; McElreavy, K.; Robevska, G.; Akloul, L.; Ghieh, F.; Sreenivasan, R.; Beaumont, M.; Bashamboo, A.; Bignon-Topalovic, J.; Neyroud, A.S.; et al. STAG3 homozygous missense variant causes primary ovarian insufficiency and male non-obstructive azoospermia. Mol. Hum. Reprod. 2020, 26, 665–677.
98. Van Der Bijl, N.; Röpke, A.; Biswas, U.; Wöste, M.; Jessberger, R.; Kliesch, S.; Friedrich, C.; Tüttelmann, F. Mutations in the stromal antigen 3 (STAG3) gene cause male infertility due to meiotic arrest. Hum. Reprod. 2019, 34, 2112–2119.
99. Nakamura, S.; Kobori, Y.; Ueda, Y.; Tanaka, Y.; Ishikawa, H.; Yoshida, A.; Katsumi, M.; Saito, K.; Nakamura, A.; Ogata, T.; et al. STX2 is a causative gene for nonobstructive azoospermia. Hum. Mutat. 2018, 39, 830–833.
100. Pashaei, M.; Rahimi Bidgoli, M.M.; Zare-Abdollahi, D.; Najmabadi, H.; Haji-Seyed-Javadi, R.; Fatehi, F.; Alavi, A. The second mutation of SYCE1 gene associated with autosomal recessive nonobstructive azoospermia. J. Assist. Reprod. Genet. 2020, 37, 451–458.
101. Maor-Sagie, E.; Cinnamon, Y.; Yaacov, B.; Shaag, A.; Goldsmidt, H.; Zenvirt, S.; Laufer, N.; Richler, C.; Frumkin, A. Deleterious mutation in SYCE1 is associated with non-obstructive azoospermia. J. Assist. Reprod. Genet. 2015, 32, 887–891.
102. Tan, Y.Q.; Tu, C.; Meng, L.; Yuan, S.; Sjaarda, C.; Luo, A.; Du, J.; Li, W.; Gong, F.; Zhong, C.; et al. Loss-of-function mutations in TDRD7 lead to a rare novel syndrome combining congenital cataract and nonobstructive azoospermia in humans. Genet. Med. 2019, 21, 1209–1217.
103. Sha, Y.; Zheng, L.; Ji, Z.; Mei, L.; Ding, L.; Lin, S.; Wang, X.; Yang, X.; Li, P. A novel TEX11 mutation induces azoospermia: A case report of infertile brothers and literature review. BMC Med. Genet. 2018, 19, 1–7.
104. Yang, F.; Silber, S.; Leu, N.A.; Oates, R.D.; Marszalek, J.D.; Skaletsky, H.; Brown, L.G.; Rozen, S.; Page, D.C.; Wang, P.J. TEX11 is mutated in infertile men with azoospermia and regulates genome-wide recombination rates in mouse. EMBO Mol. Med. 2015, 7, 1198–1210.
105. Yatsenko, A.N.; Georgiadis, A.P.; Röpke, A.; Berman, A.J.; Jaffe, T.; Olszewska, M.; Westernströer, B.; Sanfilippo, J.; Kurpisz, M.; Rajkovic, A.; et al. X-linked TEX11 mutations, meiotic arrest, and azoospermia in infertile men. N. Engl. J. Med. 2015, 372, 2097–2107.
106. Yang, Y.; Guo, J.; Dai, L.; Zhu, Y.; Hu, H.; Tan, L.; Chen, W.; Liang, D.; He, J.; Tu, M.; et al. XRCC2 mutation causes meiotic arrest, azoospermia and infertility. J. Med. Genet. 2018, 55, 628–636.
107. Ayhan, Ö.; Balkan, M.; Guven, A.; Hazan, R.; Atar, M.; Tok, A.; Tolun, A. Truncating mutations in TAF4B and ZMYND15 causing recessive azoospermia. J. Med. Genet. 2014, 51, 239–244.
108. Lopes, A.M.; Aston, K.I.; Thompson, E.; Carvalho, F.; Gonçalves, J.; Huang, N.; Matthiesen, R.; Noordam, M.J.; Quintela, I.; Ramu, A.; et al. Human spermatogenic failure purges deleterious mutation load from the autosomes and both sex chromosomes, including the gene DMRT1. PLoS Genet. 2013, 9.
109. Yin, H.; Ma, H.; Hussain, S.; Zhang, H.; Xie, X.; Jiang, L.; Jiang, X.; Iqbal, F.; Bukhari, I.; Jiang, H.; et al. A homozygous FANCM frameshift pathogenic variant causes male infertility. Genet. Med. 2019, 21, 62–70.
110. Kasak, L.; Punab, M.; Nagirnaja, L.; Grigorova, M.; Minajeva, A.; Lopes, A.M.; Punab, A.M.; Aston, K.I.; Carvalho, F.; Laasik, E.; et al. Bi-allelic Recessive Loss-of-Function Variants in FANCM Cause Non-obstructive Azoospermia. Am. J. Hum. Genet. 2018, 103, 200–212.
111. Wyrwoll, M.J.; Temel, Ş.G.; Nagirnaja, L.; Oud, M.S.; Lopes, A.M.; van der Heijden, G.W.; Heald, J.S.; Rotte, N.; Wistuba, J.; Wöste, M.; et al. Bi-allelic mutations in M1AP are a frequent cause of meiotic arrest and severely impaired spermatogenesis leading to male infertility. Am. J. Hum. Genet. 2020, 107, 342–351.
112. Ferlin, A.; Rocca, M.S.; Vinanzi, C.; Ghezzi, M.; Di Nisio, A.; Foresta, C. Mutational screening of NR5A1 gene encoding steroidogenic factor 1 in cryptorchidism and male factor infertility and functional analysis of seven undescribed mutations. Fertil. Steril. 2015, 104, 163–169.e1.
113. Zare-Abdollahi, D.; Safari, S.; Mirfakhraie, R.; Movafagh, A.; Bastami, M.; Azimzadeh, P.; Salsabili, N.; Ebrahimizadeh, W.; Salami, S.; Omrani, M.D. Mutational screening of the NR5A1 in azoospermia. Andrologia 2015, 47, 395–401.
114. Röpke, A.; Tewes, A.C.; Gromoll, J.; Kliesch, S.; Wieacker, P.; Tüttelmann, F. Comprehensive sequence analysis of the NR5A1 gene encoding steroidogenic factor 1 in a large group of infertile males. Eur. J. Hum. Genet. 2013, 21, 1012–1015.
115. Bashamboo, A.; Ferraz-De-Souza, B.; Loureno, D.; Lin, L.; Sebire, N.J.; Montjean, D.; Bignon-Topalovic, J.; Mandelbaum, J.; Siffroi, J.P.; Christin-Maitre, S.; et al. Human male infertility associated with mutations in NR5A1 encoding steroidogenic factor 1. Am. J. Hum. Genet. 2010, 87, 505–512.
116. Safari, S.; Zare-Abdollahi, D.; Mirfakhraie, R.; Ghafouri-Fard, S.; Pouresmaeili, F.; Movafagh, A.; Omrani, M.D. An Iranian family with azoospermia and premature ovarian insufficiency segregating NR5A1 mutation. Climacteric 2014, 17, 301–303.
117. Arafat, M.; Har-Vardi, I.; Harlev, A.; Levitas, E.; Zeadna, A.; Abofoul-Azab, M.; Dyomin, V.; Sheffield, V.C.; Lunenfeld, E.; Huleihel, M.; et al. Mutation in TDRD9 causes non-obstructive azoospermia in infertile men. J. Med. Genet. 2017, 54, 633–639.
118. Colombo, R.; Pontoglio, A.; Bini, M. Two novel TEX15 mutations in a family with nonobstructive azoospermia. Gynecol. Obstet. Investig. 2017, 82, 283–286.
119. Okutman, O.; Muller, J.; Baert, Y.; Serdarogullari, M.; Gultomruk, M.; Piton, A.; Rombaut, C.; Benkhalifa, M.; Teletin, M.; Skory, V.; et al. Exome sequencing reveals a nonsense mutation in TEX15 causing spermatogenic failure in a Turkish family. Hum. Mol. Genet. 2015, 24, 5581–5588.
120. Xu, J.; Jiang, L.; Yu, W.; Guo, H.; Zhang, H.; Wei, D.; Liang, L.; Feng, K.; Song, X.; Liu, Q.; et al. A novel functional variant in Wilms’ Tumor 1 (WT1) is associated with idiopathic non-obstructive azoospermia. Mol. Reprod. Dev. 2017, 84, 222–228.
121. Seabra, C.M.; Quental, S.; Lima, A.C.; Carvalho, F.; Gonçalves, J.; Fernandes, S.; Pereira, I.; Silva, J.; Marques, P.I.; Sousa, M.; et al. The mutational spectrum of WT1 in male infertility. J. Urol. 2015, 193, 1709–1715.
122. Wang, X.N.; Li, Z.S.; Ren, Y.; Jiang, T.; Wang, Y.Q.; Chen, M.; Zhang, J.; Hao, J.X.; Wang, Y.B.; Sha, R.N.; et al. The wilms tumor gene, Wt1, is critical for mouse spermatogenesis via regulation of sertoli cell polarity and is associated with non-obstructive azoospermia in humans. PLoS Genet. 2013, 9.
123. Tenenbaum-Rakover, Y.; Weinberg-Shukron, A.; Renbaum, P.; Lobel, O.; Eideh, H.; Gulsuner, S.; Dahary, D.; Abu-Rayyan, A.; Kanaan, M.; Levy-Lahad, E.; et al. Minichromosome maintenance complex component 8 (MCM8) gene mutations result in primary gonadal failure. J. Med. Genet. 2015, 52, 391–399.
124. Al-Agha, A.E.; Ahmed, I.A.; Nuebel, E.; Moriwaki, M.; Moore, B.; Peacock, K.A.; Mosbruger, T.; Neklason, D.W.; Jorde, L.B.; Yandell, M.; et al. Primary ovarian insufficiency and azoospermia in carriers of a homozygous PSMC3IP stop gain mutation. J. Clin. Endocrinol. Metab. 2018, 103, 555–563.
125. Begum, G.; Yuan, H.; Kahle, K.T.; Li, L.; Wang, S.; Shi, Y.; Shmukler, B.E.; Yang, S.S.; Lin, S.H.; Alper, S.L.; et al. Inhibition of WNK3 kinase signaling reduces brain damage and accelerates neurological recovery after stroke. Stroke 2015, 46, 1956–1965.
126. Nepal, M.; Che, R.; Zhang, J.; Ma, C.; Fei, P. Fanconi anemia signaling and cancer. Trends Cancer 2017, 3, 840–856.
127. Shimamura, A.; Alter, B.P. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev. 2010, 24, 101–122.
128. Habedanck, R.; Stierhof, Y.D.; Wilkinson, C.J.; Nigg, E.A. The Polo kinase Plk4 functions in centriole duplication. Nat. Cell Biol. 2005, 7, 1140–1146.
129. Martin, C.A.; Ahmad, I.; Klingseisen, A.; Hussain, M.S.; Bicknell, L.S.; Leitch, A.; Nürnberg, G.; Toliat, M.R.; Murray, J.E.; Hunt, D.; et al. Mutations in PLK4, encoding a master regulator of centriole biogenesis, cause microcephaly, growth failure and retinopathy. Nat. Genet. 2014, 46, 1283–1292.
130. Harris, R.M.; Weiss, J.; Jameson, J.L. Male hypogonadism and germ cell loss caused by a mutation in Polo-like kinase 4. Endocrinology 2011, 152, 3975–3985.
131. Pace, A.J.; Lee, E.; Athirakul, K.; Coffman, T.M.; O’Brien, D.A.; Koller, B.H. Failure of spermatogenesis in mouse lines deficient in the Na+-K+-2Cl− cotransporter. J. Clin. Investig. 2000, 105, 441–450.
132. Luo, M.; Yang, F.; Leu, N.A.; Landaiche, J.; Handel, M.A.; Benavente, R.; La Salle, S.; Wang, P.J. MEIOB exhibits single-stranded DNA-binding and exonuclease activities and is essential for meiotic recombination. Nat. Commun. 2013, 4.
133. Souquet, B.; Abby, E.; Hervé, R.; Finsterbusch, F.; Tourpin, S.; Le Bouffant, R.; Duquenne, C.; Messiaen, S.; Martini, E.; Bernardino-Sgherri, J.; et al. MEIOB targets single-strand DNA and is necessary for meiotic recombination. PLoS Genet. 2013, 9.
134. Caburet, S.; Todeschini, A.L.; Petrillo, C.; Martini, E.; Farran, N.D.; Legois, B.; Livera, G.; Younis, J.S.; Shalev, S.; Veitia, R.A. A truncating MEIOB mutation responsible for familial primary ovarian insufficiency abolishes its interaction with its partner SPATA22 and their recruitment to DNA double-strand breaks. EBioMedicine 2019, 42, 524–531.
135. Nakamura, S.; Miyado, M.; Saito, K.; Katsumi, M.; Nakamura, A.; Kobori, Y.; Tanaka, Y.; Ishikawa, H.; Yoshida, A.; Okada, H.; et al. Next-generation sequencing for patients with non-obstructive azoospermia: Implications for significant roles of monogenic/oligogenic mutations. Andrology 2017, 5, 824–831.
136. Moreira, M.C.; Klur, S.; Watanabe, M.; Németh, A.H.; Le Ber, I.; Moniz, J.C.; Tranchant, C.; Aubourg, P.; Tazir, M.; Schöls, L.; et al. Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat. Genet. 2004, 36, 225–227.
137. Chen, Y.Z.; Bennett, C.L.; Huynh, H.M.; Blair, I.P.; Puls, I.; Irobi, J.; Dierick, I.; Abel, A.; Kennerson, M.L.; Rabin, B.A.; et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am. J. Hum. Genet. 2004, 74, 1128–1135.
138. Wang, Y.; Chen, Y.; Chen, J.; Wang, L.; Nie, L.; Long, J.; Chang, H.; Wu, J.; Huang, C.; Lei, M. The meiotic TERB1-TERB2-MAJIN complex tethers telomeres to the nuclear envelope. Nat. Commun. 2019, 10, 1–19.
139. Gómez-H., L.; Felipe-Medina, N.; Sánchez-Martín, M.; Davies, O.R.; Ramos, I.; García-Tuñón, I.; De Rooij, D.G.; Dereli, I.; Tóth, A.; Barbero, J.L.; et al. C14ORF39/SIX6OS1 is a constituent of the synaptonemal complex and is essential for mouse fertility. Nat. Commun. 2016, 7.
140. Thorslund, T.; Esashi, F.; West, S.C. Interactions between human BRCA2 protein and the meiosis-specific recombinase DMC1. EMBO J. 2007, 26, 2915–2922.
141. Bishop, D.K.; Park, D.; Xu, L.; Kleckner, N. DMC1: A meiosis-specific yeast homolog of E. coli recA required for recombination, synaptonemal complex formation, and cell cycle progression. Cell 1992, 69, 439–456.
142. Pittman, D.L.; Cobb, J.; Schimenti, K.J.; Wilson, L.A.; Cooper, D.M.; Brignull, E.; Handel, M.A.; Schimenti, J.C. Meiotic prophase arrest with failure of chromosome synapsis in mice deficient for Dmc1, a germline-specific RecA homolog. Mol. Cell 1998, 1, 697–705.
143. Du, L.; Luo, Y. Structure of a filament of stacked octamers of human DMC1 recombinase. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2013, 69, 382–386.
144. Tock, A.J.; Henderson, I.R. Hotspots for initiation of meiotic recombination. Front. Genet. 2018, 9.
145. Bolcun-Filas, E.; Speed, R.; Taggart, M.; Grey, C.; De Massy, B.; Benavente, R.; Cooke, H.J. Mutation of the mouse Syce1 gene disrupts synapsis and suggests a link between synaptonemal complex structural components and DNA repair. PLoS Genet. 2009, 5.
146. Horn, H.F.; Kim, D.I.; Wright, G.D.; Wong, E.S.M.; Stewart, C.L.; Burke, B.; Roux, K.J. A mammalian KASH domain protein coupling meiotic chromosomes to the cytoskeleton. J. Cell Biol. 2013, 202, 1023–1039.
147. Reynolds, A.; Qiao, H.; Yang, Y.; Chen, J.K.; Jackson, N.; Biswas, K.; Holloway, J.K.; Baudat, F.; De Massy, B.; Wang, J.; et al. RNF212 is a dosage-sensitive regulator of crossing-over during mammalian meiosis. Nat. Genet. 2013, 45, 269–278.
148. Fujiwara, Y.; Ogonuki, N.; Inou, K.; Ogura, A.; Handel, M.A.; Noguchi, J.; Kunieda, T. t-SNARE syntaxin2 (STX2) is implicated in intracellular transport of sulfoglycolipids during meiotic prophase in mouse spermatogenesis. Biol. Reprod. 2013, 88.
149. Zhang, Y.X.; Li, H.Y.; He, W.B.; Tu, C.; Du, J.; Li, W.; Lu, G.X.; Lin, G.; Yang, Y.; Tan, Y.Q. XRCC2 mutation causes premature ovarian insufficiency as well as non-obstructive azoospermia in humans. Clin. Genet. 2019, 95, 442–443.
150. Herrán, Y.; Gutiérrez-Caballero, C.; Sánchez-Martín, M.; Hernández, T.; Viera, A.; Barbero, J.L.; De Álava, E.; De Rooij, D.G.; Suja, J.Á.; Llano, E.; et al. The cohesin subunit RAD21L functions in meiotic synapsis and exhibits sexual dimorphism in fertility. EMBO J. 2011, 30, 3091–3105.
151. Shibuya, H.; Ishiguro, K.I.; Watanabe, Y. The TRF1-binding protein TERB1 promotes chromosome movement and telomere rigidity in meiosis. Nat. Cell Biol. 2014, 16, 145–156.
152. Shibuya, H.; Hernández-Hernández, A.; Morimoto, A.; Negishi, L.; Höög, C.; Watanabe, Y. MAJIN links telomeric DNA to the nuclear membrane by exchanging telomere cap. Cell 2015, 163, 1252–1266.
153. Rawlings, N.D.; Tolle, D.P.; Barrett, A.J. Evolutionary families of peptidase inhibitors. Biochem. J. 2004, 378, 705–716.
154. Tanaka, T.; Hosokawa, M.; Vagin, V.V.; Reuter, M.; Hayashi, E.; Mochizuki, A.L.; Kitamura, K.; Yamanaka, H.; Kondoh, G.; Okawa, K.; et al. Tudor domain containing 7 (Tdrd7) is essential for dynamic ribonucleoprotein (RNP) remodeling of chromatoid bodies during spermatogenesis. Proc. Natl. Acad. Sci. USA 2011, 108, 10579–10584.
155. Yan, W.; Si, Y.; Slaymaker, S.; Li, J.; Zheng, H.; Young, D.L.; Aslanian, A.; Saunders, L.; Verdin, E.; Charo, I.F. Zmynd15 encodes a histone deacetylase-dependent transcriptional repressor essential for spermiogenesis and male fertility. J. Biol. Chem. 2010, 285, 31418–31426.
156. Vinci, G.; Chantot-Bastaraud, S.; El Houate, B.; Lortat-Jacob, S.; Brauner, R.; McElreavey, K. Association of deletion 9p, 46,XY gonadal dysgenesis and autistic spectrum disorder. Mol. Hum. Reprod. 2007, 13, 685–689.
157. Veitia, R.A.; Nunes, M.; Quintana-Murci, L.; Rappaport, R.; Thibaud, E.; Jaubert, F.; Fellous, M.; McElreavey, K.; Gonçalves, J.; Silva, M.; et al. Swyer syndrome and 46,XY partial gonadal dysgenesis associated with 9p deletions in the absence of monosomy-9p syndrome. Am. J. Hum. Genet. 1998, 63, 901–905.
158. Bogliolo, M.; Bluteau, D.; Lespinasse, J.; Pujol, R.; Vasquez, N.; D’Enghien, C.D.; Stoppa-Lyonnet, D.; Leblanc, T.; Soulier, J.; Surrallés, J. Biallelic truncating FANCM mutations cause early-onset cancer but not Fanconi anemia. Genet. Med. 2018, 20, 458–463.
159. Catucci, I.; Osorio, A.; Arver, B.; Neidhardt, G.; Bogliolo, M.; Zanardi, F.; Riboni, M.; Minardi, S.; Pujol, R.; Azzollini, J.; et al. Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility. Genet. Med. 2018, 20, 452–457.
160. Yan, Z.; Delannoy, M.; Ling, C.; Daee, D.; Osman, F.; Muniandy, P.A.; Shen, X.; Oostra, A.B.; Du, H.; Steltenpool, J.; et al. A Histone-fold complex and FANCM form a conserved dna-remodeling complex to maintain genome stability. Mol. Cell 2010, 37, 865–878.
161. Bakker, S.T.; van de Vrugt, H.J.; Rooimans, M.A.; Oostra, A.B.; Steltenpool, J.; Delzenne-Goette, E.; van der Wal, A.; van der Valk, M.; Joenje, H.; te Riele, H.; et al. Fancm-deficient mice reveal unique features of Fanconi anemia complementation group M. Hum. Mol. Genet. 2009, 18, 3484–3495.
162. Luo, Y.; Hartford, S.A.; Zeng, R.; Southard, T.L.; Shima, N.; Schimenti, J.C. Hypersensitivity of Primordial Germ Cells to Compromised Replication-Associated DNA Repair Involves ATM-p53-p21 Signaling. PLoS Genet. 2014, 10.
163. Saba, R.; Kato, Y.; Saga, Y. NANOS2 promotes male germ cell development independent of meiosis suppression. Dev. Biol. 2014, 385, 32–40.
164. Tsuda, M.; Sasaoka, Y.; Kiso, M.; Abe, K.; Haraguchi, S.; Kobayashi, S.; Saga, Y. Conserved role of nanos proteins in germ cell development. Science 2003, 301, 1239–1241.
165. Kusz-Zamelczyk, K.; Sajek, M.; Spik, A.; Glazar, R.; Jȩdrzejczak, P.; Latos-Bieleńska, A.; Kotecki, M.; Pawelczyk, L.; Jaruzelska, J. Mutations of NANOS1, a human homologue of the Drosophila morphogen, are associated with a lack of germ cells in testes or severe oligo-astheno-teratozoospermia. J. Med. Genet. 2013, 50, 187–193.
166. Greenbaum, M.P.; Iwamori, T.; Buchold, G.M.; Matzuk, M.M. Germ cell intercellular bridges. Cold Spring Harb. Perspect. Biol. 2011, 3, 1–18.
167. Ruan, J.; He, X.J.; Du, W.D.; Chen, G.; Zhou, Y.; Xu, S.; Zuo, X.B.; Fang, L.B.; Cao, Y.X.; Zhang, X.J. Genetic variants in TEX15 gene conferred susceptibility to spermatogenic failure in the Chinese Han population. Reprod. Sci. 2012, 19, 1190–1196.
168. Nachtigal, M.W.; Hirokawa, Y.; Enyeart-VanHouten, D.L.; Flanagan, J.N.; Hammer, G.D.; Ingraham, H.A. Wilms’ tumor 1 and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression. Cell 1998, 93, 445–454.
169. Cools, M.; Nordenström, A.; Robeva, R.; Hall, J.; Westerveld, P.; Flück, C.; Köhler, B.; Berra, M.; Springer, A.; Schweizer, K.; et al. Caring for individuals with a difference of sex development (DSD): A Consensus Statement. Nat. Rev. Endocrinol. 2018, 14, 415–429.
170. Eggers, S.; Sadedin, S.; van den Bergen, J.A.; Robevska, G.; Ohnesorg, T.; Hewitt, J.; Lambeth, L.; Bouty, A.; Knarston, I.M.; Tan, T.Y.; et al. Disorders of sex development: Insights from targeted gene sequencing of a large international patient cohort. Genome Biol. 2016, 17, 1–21.
171. Ferraz-de-Souza, B.; Lin, L.; Achermann, J.C. Steroidogenic factor-1 (SF-1, NR5A1) and human disease. Mol. Cell. Endocrinol. 2011, 336, 198–205.
172. Hastie, N.D. Wilms’ tumour 1 (WT1) in development, homeostasis and disease. Development 2017, 144, 2862–2872.
173. Kaneko, Y.; Okita, H.; Haruta, M.; Arai, Y.; Oue, T.; Tanaka, Y.; Horie, H.; Hinotsu, S.; Koshinaga, T.; Yoneda, A.; et al. A high incidence of WT1 abnormality in bilateral Wilms tumours in Japan, and the penetrance rates in children with WT1 germline mutation. Br. J. Cancer 2015, 112, 1121–1133.
174. Lourenço, D.; Brauner, R.; Lin, L.; De Perdigo, A.; Weryha, G.; Muresan, M.; Boudjenah, R.; Guerra-Junior, G.; Maciel-Guerra, A.T.; Achermann, J.C.; et al. Mutations in NR5A1 associated with ovarian insufficiency. N. Engl. J. Med. 2009, 360, 1200–1210.
175. Köhler, B.; Biebermann, H.; Friedsam, V.; Gellermann, J.; Maier, R.F.; Pohl, M.; Wieacker, P.; Hiort, O.; Grüters, A.; Krude, H. Analysis of the Wilms’ tumor suppressor gene (WT1) in patients 46,XY disorders of sex development. J. Clin. Endocrinol. Metab. 2011, 96.
176. Shoji, M.; Tanaka, T.; Hosokawa, M.; Reuter, M.; Stark, A.; Kato, Y.; Kondoh, G.; Okawa, K.; Chujo, T.; Suzuki, T.; et al. The TDRD9-MIWI2 complex is essential for piRNA-mediated retrotransposon silencing in the mouse male germline. Dev. Cell 2009, 17, 775–787.
177. Griffin, W.C.; Trakselis, M.A. The MCM8/9 complex: A recent recruit to the roster of helicases involved in genome maintenance. DNA Repair 2019, 76, 1–10.
178. Zangen, D.; Kaufman, Y.; Zeligson, S.; Perlberg, S.; Fridman, H.; Kanaan, M.; Abdulhadi-Atwan, M.; Abu Libdeh, A.; Gussow, A.; Kisslov, I.; et al. XX ovarian dysgenesis is caused by a PSMC3IP/HOP2 mutation that abolishes coactivation of estrogen-driven transcription. Am. J. Hum. Genet. 2011, 89, 572–579.
179. Zhao, W.; Sung, P. Significance of ligand interactions involving Hop2-Mnd1 and the RAD51 and DMC1 recombinases in homologous DNA repair and XX ovarian dysgenesis. Nucleic Acids Res. 2015, 43, 4055–4066.
180. Sansam, C.L.; Pezza, R.J. Connecting by breaking and repairing: Mechanisms of DNA strand exchange in meiotic recombination. FEBS J. 2015, 282, 2431–2444.
181. Petukhova, G.V.; Romanienko, P.J.; Camerini-Otero, R.D. The Hop2 protein has a direct role in promoting interhomolog interactions during mouse meiosis. Dev. Cell 2003, 5, 927–936.
182. Huhtaniemi, I.; Hovatta, O.; La Marca, A.; Livera, G.; Monniaux, D.; Persani, L.; Heddar, A.; Jarzabek, K.; Laisk-Podar, T.; Salumets, A.; et al. Advances in the molecular pathophysiology, genetics, and treatment of primary ovarian insufficiency. Trends Endocrinol. Metab. 2018, 29, 400–419.
183. Laissue, P. Aetiological coding sequence variants in non-syndromic premature ovarian failure: From genetic linkage analysis to next generation sequencing. Mol. Cell. Endocrinol. 2015, 411, 243–257.
184. Rossetti, R.; Ferrari, I.; Bonomi, M.; Persani, L. Genetics of primary ovarian insufficiency. Clin. Genet. 2017, 91, 183–198.
185. Jiao, X.; Zhang, H.; Ke, H.; Zhang, J.; Cheng, L.; Liu, Y.; Qin, Y.; Chen, Z.J. Premature ovarian insufficiency: Phenotypic characterization within different etiologies. J. Clin. Endocrinol. Metab. 2017, 102, 2281–2290.
186. Golezar, S.; Ramezani Tehrani, F.; Khazaei, S.; Ebadi, A.; Keshavarz, Z. The global prevalence of primary ovarian insufficiency and early menopause: A meta-analysis. Climacteric 2019, 22, 403–411.
187. Patiño, L.C.; Beau, I.; Carlosama, C.; Buitrago, J.C.; González, R.; Suárez, C.F.; Patarroyo, M.A.; Delemer, B.; Young, J.; Binart, N.; et al. New mutations in non-syndromic primary ovarian insufficiency patients identified via whole-exome sequencing. Hum. Reprod. 2017, 32, 1512–1520.
188. Fouquet, B.; Pawlikowska, P.; Caburet, S.; Guigon, C.; Mäkinen, M.; Tanner, L.; Hietala, M.; Urbanska, K.; Bellutti, L.; Legois, B.; et al. A homozygous FANCM mutation underlies a familial case of non-syndromic primary ovarian insufficiency. eLife 2017, 6.
189. Yang, X.; Zhang, X.; Jiao, J.; Zhang, F.; Pan, Y.; Wang, Q.; Chen, Q.; Cai, B.; Tang, S.; Zhou, Z.; et al. Rare variants in FANCA induce premature ovarian insufficiency. Hum. Genet. 2019, 138, 1227–1236.
190. Heddar, A.; Misrahi, M. Concerns regarding the potentially causal role of FANCA heterozygous variants in human primary ovarian insufficiency. Hum. Genet. 2020.
191. AlAsiri, S.; Basit, S.; Wood-Trageser, M.A.; Yatsenko, S.A.; Jeffries, E.P.; Surti, U.; Ketterer, D.M.; Afzal, S.; Ramzan, K.; Faiyaz-Ul Haque, M.; et al. Exome sequencing reveals MCM8 mutation underlies ovarian failure and chromosomal instability. J. Clin. Investig. 2015, 125, 258–262.
192. Dou, X.; Guo, T.; Li, G.; Zhou, L.G.; Qin, Y.; Chen, Z.J. Minichromosome maintenance complex component 8 mutations cause primary ovarian insufficiency. Fertil. Steril. 2016, 106, 1485–1489.e2.
193. Bouali, N.; Francou, B.; Bouligand, J.; Imanci, D.; Dimassi, S.; Tosca, L.; Zaouali, M.; Mougou, S.; Young, J.; Saad, A.; et al. New MCM8 mutation associated with premature ovarian insufficiency and chromosomal instability in a highly consanguineous Tunisian family. Fertil. Steril. 2017, 108, 694–702.
194. Heddar, A.; Beckers, D.; Fouquet, B.; Roland, D.; Misrahi, M. A novel phenotype combining primary ovarian insufficiency growth retardation and pilomatricomas with MCM8 mutation. J. Clin. Endocrinol. Metab. 2020, 105.
195. Wang, F.; Guo, S.; Li, P. Two novel mutations in the MCM8 gene shared by two Chinese siblings with primary ovarian insufficiency and short stature. Mol. Genet. Genomic Med. 2020, 8.
196. Zhang, Y.X.; He, W.B.; Xiao, W.J.; Meng, L.L.; Tan, C.; Du, J.; Lu, G.X.; Lin, G.; Tan, Y.Q. Novel loss-of-function mutation in MCM8 causes premature ovarian insufficiency. Mol. Genet. Genomic Med. 2020, 8.
197. Lutzmann, M.; Grey, C.; Traver, S.; Ganier, O.; Maya-Mendoza, A.; Ranisavljevic, N.; Bernex, F.; Nishiyama, A.; Montel, N.; Gavois, E.; et al. MCM8- and MCM9-deficient mice reveal gametogenesis defects and genome instability due to impaired homologous recombination. Mol. Cell 2012, 47, 523–534.
198. Caburet, S.; Arboleda, V.A.; Llano, E.; Overbeek, P.A.; Barbero, J.L.; Oka, K.; Harrison, W.; Vaiman, D.; Ben-Neriah, Z.; García-Tuñón, I.; et al. Mutant cohesin in premature ovarian failure. N. Engl. J. Med. 2014, 370, 943–949.
199. Le Quesne Stabej, P.; Williams, H.J.; James, C.; Tekman, M.; Stanescu, H.C.; Kleta, R.; Ocaka, L.; Lescai, F.; Storr, H.L.; Bitner-Glindzicz, M.; et al. STAG3 truncating variant as the cause of primary ovarian insufficiency. Eur. J. Hum. Genet. 2016, 24, 135–138.
200. Colombo, R.; Pontoglio, A.; Bini, M. A STAG3 missense mutation in two sisters with primary ovarian insufficiency. Eur. J. Obstet. Gynecol. Reprod. Biol. 2017, 216, 269–271.
201. He, W.B.; Banerjee, S.; Meng, L.L.; Du, J.; Gong, F.; Huang, H.; Zhang, X.X.; Wang, Y.Y.; Lu, G.X.; Lin, G.; et al. Whole-exome sequencing identifies a homozygous donor splice-site mutation in STAG3 that causes primary ovarian insufficiency. Clin. Genet. 2018, 93, 340–344.
202. França, M.M.; Nishi, M.Y.; Funari, M.F.A.; Lerario, A.M.; Baracat, E.C.; Hayashida, S.A.Y.; Maciel, G.A.R.; Jorge, A.A.L.; Mendonca, B.B. Two rare loss-of-function variants in the STAG3 gene leading to primary ovarian insufficiency. Eur. J. Med. Genet. 2019, 62, 186–189.
203. Heddar, A.; Dessen, P.; Flatters, D.; Misrahi, M. Novel STAG3 mutations in a Caucasian family with primary ovarian insufficiency. Mol. Genet. Genomics 2019, 294, 1527–1534.
204. Xiao, W.J.; He, W.B.; Zhang, Y.X.; Meng, L.L.; Lu, G.X.; Lin, G.; Tan, Y.Q.; Du, J. In-Frame Variants in STAG3 gene cause premature ovarian insufficiency. Front. Genet. 2019, 10.
205. Hopkins, J.; Hwang, G.; Jacob, J.; Sapp, N.; Bedigian, R.; Oka, K.; Overbeek, P.; Murray, S.; Jordan, P.W. Meiosis-specific cohesin component, stag3 is essential for maintaining centromere chromatid cohesion, and required for DNA repair and synapsis between homologous chromosomes. PLoS Genet. 2014, 10.
206. De Vries, L.; Behar, D.M.; Smirin-Yosef, P.; Lagovsky, I.; Tzur, S.; Basel-Vanagaite, L. Exome sequencing reveals SYCE1 mutation associated with autosomal recessive primary ovarian insufficiency. J. Clin. Endocrinol. Metab. 2014, 99, E2129–E2132.
207. Hernández-López, D.; Geisinger, A.; Trovero, M.F.; Santiñaque, F.F.; Brauer, M.; Folle, G.A.; Benavente, R.; Rodríguez-Casuriaga, R. Familial primary ovarian insufficiency associated with an SYCE1 point mutation: Defective meiosis elucidated in humanized mice. Mol. Hum. Reprod. 2020, 26, 485–497.
208. Zhe, J.; Ye, D.; Chen, X.; Liu, Y.; Zhou, X.; Li, Y.; Zhang, J.; Chen, S. Consanguineous Chinese familial study reveals that a gross deletion that includes the SYCE1 gene region is associated with premature ovarian insufficiency. Reprod. Sci. 2020, 27, 461–467.
209. Carlosama, C.; Elzaiat, M.; Patiño, L.C.; Mateus, H.E.; Veitia, R.A.; Laissue, P. A homozygous donor splice-site mutation in the meiotic gene MSH4 causes primary ovarian insufficiency. Hum. Mol. Genet. 2017, 26, 3161–3166.
210. Kneitz, B.; Cohen, P.E.; Avdievich, E.; Zhu, L.; Kane, M.F.; Hou, H.; Kolodner, R.D.; Kucherlapati, R.; Pollard, J.W.; Edelmann, W. MutS homolog 4 localization to meiotic chromosomes is required for chromosome pairing during meiosis in male and female mice. Genes Dev. 2000, 14, 1085–1097.
211. Mukherjee, S.; Ridgeway, A.D.; Lamb, D.J. DNA mismatch repair and infertility. Curr. Opin. Urol. 2010, 20, 525–532.
212. Janse, F.; De With, L.M.; Duran, K.J.; Kloosterman, W.P.; Goverde, A.J.; Lambalk, C.B.; Laven, J.S.E.; Fauser, B.C.J.M.; Giltay, J.C. Limited contribution of NR5A1 (SF-1) mutations in women with primary ovarian insufficiency (POI). Fertil. Steril. 2012, 97.
213. Adamovic, T.; Chen, Y.; Thai, H.T.T.; Zhang, X.; Markljung, E.; Zhao, S.; Nordenskjöld, A. The p.G146A and p.P125P polymorphisms in the steroidogenic factor-1 (SF-1) gene do not affect the risk for hypospadias in caucasians. Sex. Dev. 2012, 6, 292–297.
214. Bertelloni, S.; Dati, E.; Baldinotti, F.; Toschi, B.; Marrocco, G.; Sessa, M.R.; Michelucci, A.; Simi, P.; Baroncelli, G.I. NR5A1 gene mutations: Clinical, endocrine and genetic features in two girls with 46,XY disorder of sex development. Horm. Res. Paediatr. 2014, 81, 104–108.
215. Köhler, B.; Lin, L.; Ferraz-de-Souza, B.; Wieacker, P.; Heidemann, P.; Schröder, V.; Biebermann, H.; Schnabel, D.; Grüters, A.; Achermann, J.C. Five novel mutations in steroidogenic factor 1 (SF1, NR5A1) in 46,XY patients with severe underandrogenization but without adrenal insufficiency. Hum. Mutat. 2008, 29, 59–64.
216. Philibert, P.; Paris, F.; Lakhal, B.; Audran, F.; Gaspari, L.; Saâd, A.; Christin-Maître, S.; Bouchard, P.; Sultan, C. NR5A1 (SF-1) gene variants in a group of 26 young women with XX primary ovarian insufficiency. Fertil. Steril. 2013, 99, 484–489.e1.
217. Voican, A.; Bachelot, A.; Bouligand, J.; Francou, B.; Dulon, J.; Lombès, M.; Touraine, P.; Guiochon-Mantel, A. NR5A1 (SF-1) mutations are not a major cause of primary ovarian insufficiency. J. Clin. Endocrinol. Metab. 2013, 98.
218. Bertrand-Delepine, J.; Manouvrier-hanu, S.; Cartigny, M.; Paris, F.; Mallet, D.; Philibert, P.; Morel, Y.; Lefevre, C.; Dewailly, D.; Catteau-jonard, S. In cases of familial primary ovarian insufficiency and disorders of gonadal development, consider NR5A1/SF-1 sequence variants. Reprod. Biomed. Online 2020, 40, 151–159.
219. Lynch, D.R.; Braastad, C.D.; Nagan, N. Ovarian failure in ataxia with oculomotor apraxia type 2. Am. J. Med. Genet. Part A 2007, 143, 1775–1777.
220. Pérez de Nanclares, G.; Castaño, L.; Bilbao, J.R.; Vallo, A.; Rica, I.; Vela, A.; Martul, P. Molecular analysis of Frasier syndrome: Mutation in the WT1 gene in a girl with gonadal dysgenesis and nephronophthisis. J. Pediatr. Endocrinol. Metab. 2002, 15, 1047–1050.
221. Barbaux, S.; Niaudet, P.; Gubler, M.C.; Grünfeld, J.P.; Jaubert, F.; Kuttenn, F.; Fékété, C.N.; Souleyreau-Therville, N.; Thibaud, E.; Fellous, M.; et al. Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat. Genet. 1997, 17, 467–470.
222. Sha, Y.-W.; Sha, Y.-K.; Ji, Z.-Y.; Mei, L.-B.; Ding, L.; Zhang, Q.; Qiu, P.-P.; Lin, S.-B.; Wang, X.; Li, P.; et al. TSGA10 is a novel candidate gene associated with acephalic spermatozoa. Clin. Genet. 2017, 93, 776–783.
223. Wang, H.; Li, G.; Zhang, J.; Gao, F.; Li, W.; Qin, Y.; Chen, Z.J. Novel WT1 missense mutations in han Chinese women with premature ovarian failure. Sci. Rep. 2015, 5.
224. Dickinson, M.E.; Flenniken, A.M.; Ji, X.; Teboul, L.; Wong, M.D.; White, J.K.; Meehan, T.F.; Weninger, W.J.; Westerberg, H.; Adissu, H.; et al. High-throughput discovery of novel developmental phenotypes. Nature 2016, 537, 508–514.